Moreover, the 36-month beta value for APYX is 1.22. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for APYX is 32.16M and currently, short sellers hold a 0.93% of that float. On June 25, 2025, APYX’s average trading volume was 190.64K shares.
APYX) stock’s latest price update
The stock of Apyx Medical Corp (NASDAQ: APYX) has increased by 140774 when compared to last closing price of 2.0.Despite this, the company has seen a gain of 22.04% in its stock price over the last five trading days. prnewswire.com reported 2025-05-30 that Highlighting Real Patient Journeys and Empowering Confidence Through Loose Skin Solutions and Body Contouring CLEARWATER, Fla., May 30, 2025 /PRNewswire/ — Apyx® Medical Corporation (NASDAQ: APYX) (“Apyx Medical” or the “Company”), the manufacturer of the proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, is once again taking center stage—this time at Miami Swim Week.
APYX’s Market Performance
APYX’s stock has risen by 22.04% in the past week, with a monthly rise of 36.75% and a quarterly rise of 64.49%. The volatility ratio for the week is 9.17% while the volatility levels for the last 30 days are 6.15% for Apyx Medical Corp The simple moving average for the past 20 days is 29.00% for APYX’s stock, with a 66.65% simple moving average for the past 200 days.
Analysts’ Opinion of APYX
Stephens, on the other hand, stated in their research note that they expect to see APYX reach a price target of $8. The rating they have provided for APYX stocks is “Overweight” according to the report published on July 14th, 2023.
Lake Street gave a rating of “Buy” to APYX, setting the target price at $12 in the report published on May 20th of the previous year.
APYX Trading at 61.09% from the 50-Day Moving Average
After a stumble in the market that brought APYX to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 8.10% of gains for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APYX starting from HILL MATTHEW C, who purchase 5,336 shares at the price of $1.13 back on Aug 13 ’24. After this action, HILL MATTHEW C now owns 7,836 shares of Apyx Medical Corp, valued at $6,030 using the latest closing price.
Stock Fundamentals for APYX
Current profitability levels for the company are sitting at:
- -0.32 for the present operating margin
- 0.52 for the gross margin
The net margin for Apyx Medical Corp stands at -0.42. The total capital return value is set at -0.3. Equity return is now at value -130.26, with -30.62 for asset returns.
Based on Apyx Medical Corp (APYX), the company’s capital structure generated 0.31 points at debt to capital in total, while cash flow to debt ratio is standing at -2.59. The debt to equity ratio resting at 0.46. The interest coverage ratio of the stock is -4.87.
Currently, EBITDA for the company is -16.8 million with net debt to EBITDA at 1.82. When we switch over and look at the enterprise to sales, we see a ratio of 1.26. The receivables turnover for the company is 4.06for trailing twelve months and the total asset turnover is 0.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.45.
Conclusion
To wrap up, the performance of Apyx Medical Corp (APYX) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
